​

Funding Round

Series B - Nucleai

Series B - Nucleai

Investment Firm

Overview

Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes.

Announced Date

Mar 22, 2022

Closed on Date

Mar 22, 2022

Funding Type

Series B

Highlights

Location

Asia

Social

Investor Lead

Section 32

Section 32

Section 32 is a early_stage_venture and late_stage_venture and seed and venture firm.

Sanofi Ventures

Sanofi Ventures

Sanofi Ventures is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

4

Investor Name
Participant InvestorDebiopharm Innovation Fund
Participant InvestorSanofi Ventures
Participant InvestorSection 32
Participant InvestorGrove Ventures

Round Details and Background

Nucleai raised $33000000 on 2022-03-22 in Series B

Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 05, 2018
Seed Round - Nucleai
4-5.0M
Jul 07, 2020
Series A - Nucleai
3-8.5M
Mar 22, 2022
Series B - Nucleai
6-33.0M
Apr 03, 2024
Venture Round - Nucleai
3-14.0M

Recent Activity

There is no recent news or activity for this profile.